Associated Papers
ATPase-deficient CHD7 disease variant disrupts neural development via chromatin dysregulation.
Wang G et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao, 2025
Chromatin Remodulator CHD4: A Potential Target for Cancer Interception.
Goswami K et al.
Genes, 2025
Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer.
Novillo A et al.
Frontiers in Oncology, 2021
Nucleosome-CHD4 chromatin remodeler structure maps human disease mutations.
Farnung L et al.
Elife, 2020
Characterization of colibactin-associated mutational signature in an Asian oral squamous cell carcinoma and in other mucosal tumor types.
Boot A et al.
Genome Research, 2020
32661091 (PubMed )
Supplement: supp_gr.255620.119_Supplemental_Table_S2.xlsx › Sheet1
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Drivers-not-HR
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
29604063 (PubMed )
Supplement: PATH-245-283-s022.xlsx › CRC.Drivers.Edited
Tumour-associated missense mutations in the dMi-2 ATPase alters nucleosome remodelling properties in a mutation-specific manner.
Kovač K et al.
Nature Communications, 2018
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
Le Gallo M et al.
Nature Genetics, 2012
23104009 (PubMed )
Supplement: NIHMS412622-supplement-1.pdf
Select a paper to view details